Business Wire

ALL-IN-ON-GREEN

12.12.2022 07:01:35 CET | Business Wire | Press release

Share
All In On Green: Many Tonnes of Waste Flow Into the Sea From the World’s Rivers: a Danish Robot Minimises This Pollution

At least 70 cities in Europe can now prevent huge amounts of waste from ending up in the sea. This has been demonstrated in the city of Aarhus in Denmark, where the robot SeaProtectorOne, made by All In On Green, collected over 100,000 pieces of waste from the city’s river in just 20 months. The technology thus shows how much pollution the city is otherwise sending into the marine environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221211005006/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Many tonnes of waste flow into the sea from the world’s rivers: A Danish robot minimises this pollution (Photo: Business Wire)

Once waste enters the oceans, removing it is extremely difficult. This is why a Danish robotics invention is tackling the problem before it happens. The robot SeaProtectorOne is installed at the river mouth in Aarhus, where the river flows into the harbour and wider sea. The robot collects the waste—things like plastic cups, facemasks and pizza boxes—before it pollutes the sea. At the same time, it allows boats and other marine vessels to pass by.

SeaProtectorOne could also limit sea pollution from rivers in at least 70 other cities in Europe. This potential has been shown by thorough studies of the cities’ local conditions carried out by the team that has developed SeaProtectorOne. Kim Gulvad Svendsen, COO, Aarhus Municipality, readily shares his positive experience with this new weapon in the fight to prevent sea pollution.

“After the trial period, we were surprised at just how effective the robot was and by how much waste – especially plastic – it removed. This is plastic that will no longer end up in our marine environment. So the robot supports Aarhus Municipality’s sustainability efforts and above all, the UN’s global sustainable development goal no. 14: Life Below Water,” said Kim Gulvad Svendsen.

Every year, the amount of plastic waste that ends in the oceans is equivalent in weight to 57,000 blue whales. At least 90% of the plastic waste that floats around in the oceans, ends in the sea via river systems, according to the periodical Environmental Science.

“Once waste enters the sea it spreads quickly and is difficult to collect. Whereas the current in a river allows for the systematic filtering of waste in a limited area without disturbing fish or birds,” said Peter Grønkjær, Professor of Marine Biology at the Aarhus University.

Mads Tranders Nielsen from All In On Green is the man who invented SeaProtectorOne.

“In an ideal world, every citizen everywhere would learn to always put waste into a waste bin. But we don’t live in an ideal world. The idea for the robot came to me when I saw huge amounts of waste floating in a river in Melbourne. SeaProtectorOne has now shown its worth, even in Aarhus, one of Europe’s greenest cities. So, I’m looking forward to bringing this technology to the rest of the world for the benefit of the marine environment, fish and birds,” said Mads Tranders Nielsen from All In On Green.

Press Photos

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221211005006/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye